Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
BIOCRYST PHARMACEUTICALS INC
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-9.6% vs price
Base Case (Median)
71.4% vs price
Bull Case (75th pct.)
167.6% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| EV/EBITDA | $13.97 | 71.4% | Medium (20%) |
| EV/FCF | $29.65 | 263.8% | Medium (20%) |
| Earnings Power Value | $0.76 | -90.6% | Medium (50%) |
Based on 3 out of 7 methods, BCRX appears fairly valued at the current price of $8.15. The base case fair value of $13.97 implies 71.4% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.